NCT00001805 2008-03-04A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by RituximabNational Institutes of Health Clinical Center (CC)Phase 2 Completed20 enrolled